DXR - NASDAQ
Daxor Corporation
$11.09
+7.6%Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.
At a Glance
Live SnapshotDaxor Corporation Management Team
Mr. Michael Richard Feldschuh
Chairman, President & Chief Executive Officer
Compensation
$100,000
Mr. Robert J. Michel CPA, CPA, M.B.A.
Chief Financial Officer, Chief Compliance Officer & Corporate Secretary
Dr. John Lynn Jefferies FACC, M.B.A., M.D., M.P.H.
Chief Medical Officer
Mr. Jonathan Adam Feldschuh
Chief Scientific Officer & Director
Compensation
$127,920
Ms. Kathryn A. Kornafel
Senior Vice President of Marketing & Commercial Development
Ms. Linda Cooper
Vice President of Development & Operations
Daxor Corporation Insider Positioning
During the last 12 months, insiders have purchased $112K and sold $2K worth of DXR shares, resulting in $110K of net buying activity.
3 Months
2.0K
18.97K
0
0.00
+19K
+$19K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
145
1.75K
-2K
-$2K
9-12 Months
10.0K
92.90K
0
0.00
+93K
+$93K
Top Buyers
Goudie Joy S.
Director
$23K
Cremisi Henry D.
Director
$23K
Feuer Edward
Director
$23K
Desrosiers Caleb
Director
$23K
Michel Robert J
Officer: Chief Financial Officer
$10K
Top Sellers
Jefferies John
Officer: Chief Medical Officer
$2K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $110K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
SEC Filings
DXR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | June 03, 2026 | June 03, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | June 06, 2025 | June 06, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | June 21, 2024 | June 21, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | June 21, 2023 | June 21, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | May 31, 2022 | May 31, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | June 02, 2021 | June 02, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | June 04, 2020 | June 04, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | May 30, 2019 | May 30, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | May 22, 2018 | May 22, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | November 14, 2017 | May 22, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.